CONTACT:Tim LynchChief Financial OfficerInterMune650firstname.lastname@example.org
Lilian SternStern Investor Relations212email@example.com
Steve CragleEdelman Public Relations415firstname.lastname@example.org
INTERMUNE LICENSES INFERGEN FROM AMGEN
FOR IMMEDIATE RELEASE:
BURLINGAME, CA, June 15, 2001,InterMune, Inc. (Nasdaq: ITMN) today announced that it has signed an agreement to license Infergen (Interferon alfacon-1) from Amgen Inc. Infergen is a therapeutic approved by the FDA for the treatment of chronic hepatitis C infections, which was developed and commercialized by Amgen.
The agreement provides InterMune with exclusive rights to develop and commercialize Infergen, as well as an early stage pegylated interferon product candidate being developed by Amgen, in the United States and Canada. Amgen will supply Infergen to InterMune. The agreement includes a $21 million up-front payment to Amgen, near-term performance milestone payments of up to $8 million, additional milestone payments on the pegylated interferon program and royalties on both products.
W. Scott Harkonen, M.D., Chairman and Chief Executive Officer of InterMune, said, "We are delighted to form this relationship with Amgen, a world leader in biotechnology. With Infergen, InterMune now has three marketed products. We expect that over the next 18 months, four ongoing studies totaling over 1,000 patients will provide new clinical data relating to Infergen. In addition, we see further development potential for Infergen, which fits well with our existing programs for Actimmune in the areas of oncology and liver fibrosis associated with hepatitis C infections."
Kevin Sharer, Chairman and Chief Executive Officer of Amgen, said, "Infergen is valuable but fell outside our defined therapeutic areas of interest. We are pleased to be able to license Infergen to InterMune, a company with the focus, development resources and commercialization team able to maximize Infergen's potential."
Infergen is currently approved as treatment for adult patients with chronic hepatitis C infections, including therapy for patients who have never been treated with interferons and for patients following relapse or treatment non-response to certain previous treatments. Infergen is the only interferon approved for the treatment of patients who have failed other treatments for chronic hepatitis C infections.
INTERMUNE LICENSES INFERGEN FROM AMGENPage 2
Hepatitis C virus is the most common form of chronic hepatitis infection in North America and Europe, with close to four million adults infected in the United States. If not detected and treated, hepatitis C may lead to chronic liver disease, including liver cancer, and ranks second to alcoholism as a cause of cirrhosis.
InterMune will hold a conference call at 2:00 p.m. Eastern Time on Friday, June 15, 2001 to discuss the license of Infergen from Amgen and updated financial guidance. Interested investors and others may listen to the call live through an Internet webcast, which may be accessed by visiting InterMune's website at http://www.intermune.com and clicking on the "Investor Relations" icon. InterMune is developing and commercializing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune markets its lead product, Actimmune, for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. InterMune is currently conducting a Phase III clinical trial with Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF). InterMune is also conducting or planning clinical trials of Actimmune for the treatment of multidrug-resistant tuberculosis (MDR TB), atypical mycobacterial infections, ovarian cancer, cryptococcal meningitis, cystic fibrosis, liver fibrosis and non-Hodgkin's lymphoma. InterMune also markets Amphotec worldwide for the treatment of invasive aspergillosis.
Except for the historical information contained herein, this press release contains certain forward-looking statements concerning the possible development and commercial benefits of Infergen and the pegylated form of Infergen that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune's most recent periodic reports (i.e., 10-K, 10-Q, and 8-K) and Form S-3 filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune's efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; the uncertain, lengthy and expensive regulatory process; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors' reimbursement policies; competition from other products; and product liability lawsuits.
# # #
Tim LynchChief Financial OfficerInterMune650email@example.com
INTERMUNE ANNOUNCES UPDATED 2001 FINANCIAL GUIDANCE ANDCONFERENCE CALL2001 Revenue Goal For Actimmune Increased to $31 Million
BURLINGAME, CA, June 15, 2001 InterMune, Inc. (Nasdaq: ITMN) announced today updated 2001 financial guidance, including new product revenue goals. The new financial guidance reflects the Company's recent corporate development activities, including the license of Infergenfrom Amgen Inc. (Nasdaq: AMGN) also announced today, as well as the expansion of development programs for Actimmune and other activities since the Company's previous guidance on February 15, 2001.
The Company's 2001 net revenue goal for Actimmune is now $31 million, a $5 million increase over the Company's 2001 net revenue goal for Actimmune of $26 million most recently stated on April 25, 2001. Quarterly net sales goals for Actimmune for the remainder of 2001 are now $7.0 million in the second quarter, $8.6 million in the third quarter, and $10.5 million in the fourth quarter. The 2001 goal for the Company's total net product sales for Actimmune, Infergen and Amphotec combined is $35 million.
The Company's guidance for its 2001 research and development expenses was approximately $32 million, as of February 15, 2001. Since then, the Company has expanded its development activities through the following:
With the broad expansion of the Company's development activities and resources, including new clinical programs for Actimmune and Infergen which address major commercial opportunities, research and development expenses are currently expected to be approximately $40-$44 million in 2001, as compared with the Company's earlier guidance of $32 million.
The Company's guidance for its 2001 selling, general and administrative expenses was approximately $24 million as of February 15, 2001. Selling, general and administrative expenses are currently expected to be approximately $28-$30 million in 2001 as a result of the Company's re-launch of Infergen and increased corporate infrastructure to support expanded activities.
The Company's February 15, 2001 guidance for its 2001 net losses was approximately $36 million. Net losses are currently expected to be approximately $50-$55 million in 2001, including contribution from product sales, interest income on existing cash balances and approximately $10 million in recurring non-cash expenses, such as amortization of product rights and deferred compensation. Accordingly, 2001 net operating cash burn associated with net losses (which excludes the approximately $10 million in recurring non-cash expenses) is expected to be approximately $40-$45 million. The net loss guidance for 2001 does not reflect up to $8 million in near-term milestone payments to Amgen related to the license of Infergen and the pegylated Infergen program, some or all of which may occur in 2001. InterMune continues to target profitability by the end of 2003.
InterMune will hold a conference call at 2:00 p.m. Eastern Time on Friday, June 15, 2001 to discuss the license of Infergen from Amgen and updated financial guidance. Interested investors and others may listen to the call live through an Internet webcast, which may be accessed by visiting InterMune's website at http://www.intermune.com and clicking on the "Investor Relations" icon.
InterMune is developing and commercializing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune markets its lead product, Actimmune, for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. InterMune is currently conducting a Phase III clinical trial with Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF). InterMune is also conducting or planning clinical trials of Actimmune for the treatment of multidrug-resistant tuberculosis (MDR TB), atypical mycobacterial infections, ovarian cancer, cryptococcal meningitis, cystic fibrosis, liver fibrosis and non-Hodgkin's lymphoma. InterMune recently acquired rights to Infergen, which is marketed in the United States and Canada for the treatment of chronic hepatitis C infections. InterMune also markets Amphotec worldwide for the treatment of invasive aspergillosis.
Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning the possible revenues, expenses and programs of InterMune, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune's most recent periodic reports (i.e., 10-K, 10-Q and 8-K) and Form S-3 filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune's efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; the uncertain, lengthy and expensive regulatory process; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors' reimbursement policies; competition from other products; and product liability lawsuits.
IMMUNOMEDICS IN DISCUSSIONS TO REGAIN
DEVELOPMENT RIGHTS FROM AMGEN
Morris Plains, NJ, November 11, 2003 Immunomedics, Inc. (Nasdaq: IMMU) today announced that it is in advanced discussions with Amgen (Nasdaq: AMGN) concerning the possible return to Immunomedics of North American and Australian development rights of epratuzumab, the humanized monoclonal antibody therapeutic licensed to Amgen in December 2000. Several months ago, the parties had attempted to negotiate an expanded license agreement that would have given Amgen global development rights, but were unable to agree on terms. More recently, Amgen advised Immunomedics that due to a reassessment of its product portfolio, Amgen had decided not to proceed with a registration trial.
While it is too early to determine where these discussions will lead, we are in agreement with Amgen that the foremost objective is the continued development and commercialization of epratuzumab, only now potentially on a worldwide basis. Epratuzumab offers hope to patients suffering from non-Hodgkins lymphoma (NHL) where other treatments have failed, and we are pleased that Amgen shares our interest in our completing the development of this drug as quickly as possible. We hope to be in a position to identify an appropriate licensing partner without a significant delay and with the ability to complete the global development of the product, commented Company President and Chief Executive Officer, Cynthia L. Sullivan. We do not anticipate that this change will impact the ongoing trials being pursued by the National Cancer Institutes two study groups, ECOG and SWOG, Ms. Sullivan further commented.
In both single- and multi-center clinical trials of epratuzumab given alone or in combination with rituximab, the agent has been found to be safe, well-tolerated in 1-hour infusions, and active in the treatment of NHL patients, as communicated at various scientific meetings over the past two years as well as in an article published recently in TheJournal of Clinical Oncology, remarked Ivan D. Horak, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer at Immunomedics.
We are pleased with the additional clinical data being presented by Amgen investigators at the forthcoming meeting of the American Society of Hematology (ASH), showing further evidence of both the safety and activity of epratuzumab in NHL. The efficacy results in the multi-center trial of epratuzumab combined with rituximab are lower than those observed at the single-institution study at New York Hospital, presented at ASH in the past, suggesting that different patient populations were studied. This points to the need of a randomized trial, as is usually conducted in such settings, Dr. Horak elaborated.
Dr. Horak also said: We now have early evidence that epratuzumab is also well-tolerated in patients with autoimmune disease, and are moving forward rapidly to complete the single-agent Phase I trial in these potentially new indications.
Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and other sites of disease. Immunomedics has six therapeutic product candidates in clinical development and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide (epratuzumab), for which certain Phase II clinical trials for the treatment of non-Hodgkins lymphoma have already been completed, and CEA-Cide (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.
This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Companys Annual Report on Form 10-K for the year June 30, 2003.
Company Contact: Investor Relations, (973) 605-8200. Visit the Companys web site at http://www.Immunomedics.com
Investors: Myesha Edwards, InterMune, Inc., 415-466-2242, firstname.lastname@example.orgMedia: Ian McConnell, WeissCom Partners, Inc. 415-362-5018, email@example.com
BRISBANE, Calif., October 30, 2003 ? InterMune, Inc. (Nasdaq: ITMN) today . . .
Elizabeth Hougen, Vice President, Finance
Karen Lundstedt, Vice President, Corporate Communications
Isis Pharmaceuticals, Inc. 760-931-9200
CARLSBAD, Calif., November 4, 2003 ? Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter of 2003. The company?s loss from operations was $19.1 million and $57.5 million for the three and nine months ended . . .
CARLSBAD, Calif., August 5, 2003 ? Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the second quarter of 2003. The company?s loss from operations was $19.5 million and $38.4 million for the three and six . . .
Isis Pharmaceuticals, 760-931-9200
ISIS PHARMACEUTICALS REPORTS FINANCIAL RESULTS
AND HIGHLIGHTS FOR THE FIRST QUARTER 2003
CARLSBAD, CA May 8, 2003 ? Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its financial results for the first quarter of 2003. Total revenue for the three months ended March 31, 2003 totaled $14.0 million, compared with $18.0 . . .
ISIS PHARMACEUTICALS UPDATES OPERATING PLAN FOR 2003
Company implements employee stock option exchange programand provides financial guidance for the year
CARLSBAD, CA April 2, 2003?Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its updated operating plan and the implementation of an employee stock option exchange program and provided financial guidance for 2003. The operating plan enables the company to continue to aggressively . . .
Contacts: Elizabeth Hougen, Vice President, FinanceKaren Lundstedt, Vice President, Corporate CommunicationsIsis Pharmaceuticals, Inc. 760-931-9200http://www.isispharm.com
ISIS PHARMACEUTICALS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR 2003
CARLSBAD, Calif., February 10, 2004 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its financial results for the year-ended December 31, 2003. The companys loss from operations for 2003 was $79.0 million compared to $50.8 million in 2002, according to generally accepted accounting principles (GAAP). Consistent with its guidance, the companys loss from operations for 2003 on a proforma basis was $76.3 million, which is adjusted from GAAP to exclude non-cash compensation charges of $913,000 and restructuring charges of $1.8 million. This compared to a proforma loss from operations in 2002 of $52.4 million, which excludes $3.0 million in non-cash compensation benefit and restructuring charges of $1.4 million.
Total revenue for the quarter and year-ended December 31, 2003 was $9.7 million and $50.0 million, respectively, compared to $21.9 million and $80.2 million for the same periods in 2002. The decrease in revenue was primarily due to the reduction in revenue associated with the clinical development of Affinitak and the conclusion of Elan Corporation plc.s participation in the HepaSense and Orasense collaborations. In late 2002, Isis terminated its collaborations with Elan and reacquired rights to ISIS 14803 and the oral formulation of ISIS 104838. The decrease in revenue was offset in part by new sources of revenue not present in 2002, including the achievement of milestones in the discovery and development of drugs for our partners Eli Lilly and Company, Amgen, and the Industrial Research Institute of Taiwan (ITRI), in addition to increased revenue related to our TIGER diagnostic program.
As illustrated in the Selected Financial Information in this press release, operating expenses on a proforma basis for the quarter and year-ended December 31, 2003 were $31.2 million and $126.3 million, respectively, compared to $31.7 million and $132.6 million for the same periods in 2002. These decreases were attributed primarily to planned expense reductions during 2003.
Total operating expenses for the year-ended December 31, 2003 included a charge of approximately $913,000 in non-cash compensation expense due to variable accounting for stock options associated primarily with the employee stock option exchange program that was offered in the second quarter of 2003. For the year-ended 2002, the company reported compensation benefit of $3.0 million associated primarily with an employee option exchange program offered in January 2000. All options in the 2000 program were
either exercised or cancelled by the end of 2002 and had no impact on the companys financial statements in 2003. Variable stock options can result in significant non-cash increases and decreases in compensation expense as a result of the variability in the companys stock price.
The 2003 year-to-date operating expenses included a restructuring charge of $1.8 million related to Isis expense reduction plan, which included a small reduction in its workforce, as compared to restructuring charges of approximately $1.4 million in 2002 related to Isis termination of the Genetrove database product and write down of certain intellectual property.
Thope companys net loss applicable to common stock for the quarter and year-ended December 31, 2003 was $25.6 million, or $0.46 per share, and $95.7 million, or $1.73 per share, respectively, compared with a net loss applicable to common stock of $16.0 million, or $0.29 per share, and $73.3 million, or $1.35 per share, for the same periods last year. The increase in the net loss applicable to common stock was primarily a result of the increase in loss from operations.
Isis maintained a strong balance sheet at the end of the year with $215.5 million in cash and short-term investments and working capital of $194.0 million. At December 31, 2002, Isis had cash and short-term investments of $289.4 million and working capital of $244.2 million. Cash and short-term investments and working capital decreased primarily as a result of cash used in operations.
Isis 2003 and Recent Highlights
In 2003, we reported our first clinical results with two second-generation antisense drugs, ISIS 104838 in rheumatoid arthritis and ISIS 113715 for type 2 diabetes. The positive data indicate that second-generation drugs are an important improvement over first-generation antisense, particularly in terms of potency, side effect profile, patient convenience and cost of therapy. We also initiated clinical trials with our first cardiovascular compound, ISIS 301012, which was shown to be a potent cholesterol- lowering agent in preclinical studies, stated B. Lynne Parshall, Isis Executive Vice President and CFO. As evidence of our steady progress in antisense drug development, we plan to report data from clinical trials of eight different antisense drugs across all phases of development during the course of 2004. Our strategy of developing a broad pipeline gives us many opportunities for clinical success. Importantly, we have the financial resources to aggressively advance the development of our products.
Beyond our pipeline, we continue to realize value from other key assets, including our intellectual property estate. The progress of Macugen for the treatment of age-related macular degeneration illustrates the value within our patent estate, given Isis royalty position in this drug. In 2003, Pfizer and Eyetech reported encouraging Phase 3 data for Macugen that will serve as the basis for an NDA, with commercialization of the drug expected in 2005. Eyetech licensed several Isis chemistry patents for the development of Macugen, an aptamer. Assuming successful commercialization of Macugen, Isis has the opportunity to earn milestone payments and royalties that will be
meaningful to us, continued Ms. Parshall. We are committed to further exploiting our leadership position in RNA-based drug discovery and development for the benefit of our shareholders.
Advanced Antisense Drug Development:
Reported results from eight clinical trials:
Rheumatoid Arthritis (RA): in a Phase 2 study, ISIS 104838 produced a statistically significant disease response in evaluable patients with RA that received the two highest doses; an initial study showed the drug was distributed to synovial tissue and reduced TNF-alpha mRNA levels in synovium in a dose-dependent manner
Hepatitis C (HCV): in a Phase 2 single-agent study, ISIS 14803 decreased viral levels in a dose-dependent manner in patients who failed previous treatment
Type 2 Diabetes: in a Phase 1 study, ISIS 113715 decreased the amount of insulin required by normal volunteers to normalize blood glucose tolerance tests following a glucose challenge
Pouchitis/Ulcerative Colitis (UC): in a Phase 2 study of patients with pouchitis, alicaforsen (ISIS 2302) enema improved clinical disease symptoms with remissions that lasted up to nine months
Anticancer studies including a Phase 3 trial of Affinitak in combination with chemotherapy in patients with non-small cell lung cancer, which resulted in data that were not sufficient to support single-study registration of the drug, and two Phase 2 studies of ISIS 2503 in combination with chemotherapy that suggested activity in patients with pancreatic and breast cancers
Began five new clinical initiatives on its own or with partners:
Phase 1 trial of ISIS 301012 for cardiovascular disease
Phase 1 trial of ISIS 107248 (ATL 1102) for multiple sclerosis with partner Antisense Therapeutics Limited (ATL)
Phase 2 trial of ISIS 14803 in addition to standard HCV treatments
Phase 2 program for ISIS 113715 in patients with type 2 diabetes
Second Phase 2 trial of Alicaforsen for the treatment of ulcerative colitis
Received a grant and subsequently achieved two milestones in its antisense drug discovery partnership with ITRI of Taiwan, focused on the coronavirus associated with Severe Acute Respiratory Syndrome (SARS)
Received a grant from the Singapore Economic Development Board to support the broadening of two of Isis RNA-based drug discovery and development programs: micro-RNA drug discovery and antisense drug discovery targeting the coronavirus associated with SARS
Expanded drug discovery partnership with OncoGenex Technologies Inc. to include the development of OGX-225, a second-generation antisense anti-cancer drug that is designed to inhibit the production of two related proteins simultaneously
Initiated a multi-year collaboration to discover antisense drugs that regulate alternative RNA splicing with Ercole Biotech, Inc. Ercole licensed Isis Bcl-x preclinical antisense drug as its lead development compound
Achieved a $1.5 million milestone from Lilly for the selection of LY2181308 for clinical development. LY2181308 is an antisense inhibitor of survivin and a product of the antisense drug discovery collaboration between Isis and Lilly
Achieved a second milestone in its antisense drug discovery collaboration with Amgen
Entered into a target validation agreement with Pfizer, Inc., in which Pfizer obtained access to Isis antisense inhibitors and acquired a license to specific patents within Isis intellectual property estate for use in its internal antisense-based functional genomics program
Furthered Ibis Diagnostic Program:
Received a three-year grant for $6 million from the Centers for Disease Control and Prevention (CDC) to develop and apply Ibis diagnostic technology to the surveillance of infectious disease in the U.S.
Strengthened Isis Financial Position
Retired approximately $32 million in partner debt using a new five-year, secured 4% variable rate term loan. The retired convertible partner debt was due from 2003 to 2005 and carried interest rates ranging from 8.5% to 12%.
Reached a mutually beneficial renegotiation of Isis manufacturing relationship with Lilly. Lilly waived repayment of the $21 million manufacturing loan it provided Isis to build Isis second manufacturing facility. Lilly also agreed to allow Isis to use the facility to manufacture other drugs. In exchange, Isis released Lilly from its obligations to purchase additional Affinitak from Isis and to pay for the costs of maintaining an idle manufacturing suite
2004 Clinical Goals Isis Products
Report results of Phase 3 studies of alicaforsen in Crohns disease second half 2004
Report results of Phase 2 studies of alicaforsen in ulcerative colitis second half 2004
Report results of Phase 2 trial of ISIS 113715 in type 2 diabetes second half 2004 or early 2005
Report preliminary results of Phase 2 study of ISIS 14803 in combination with current HCV therapies second half 2004
Report results of Phase 1 study of ISIS 301012 in cardiovascular disease second half 2004
Initiate Phase 2 clinical trial of ISIS 104838 in patients with rheumatoid arthritis to refine dose and schedule second half 2004
2004 Clinical Goals - Isis Partnered Products
Report results of Lillys Phase 3 study of Affinitak in non-small cell lung cancer second half 2004
Report Phase 1 / 2 results of ISIS 112989 (OGX-011) in prostate cancer and other tumor types (OncoGenex) first half 2004
Report final Phase 1 results of ISIS 107248 (ATL 1102) in multiple sclerosis (ATL) mid 2004; initiate Phase 2 trial second half 2004
Initiate clinical trials of LY2181308, an antisense inhibitor of survivin, for cancer (Lilly) mid 2004
Isis will conduct a live webcast conference call to discuss this earnings release on Tuesday, February 10 at 8:30 am Eastern time. To participate over the Internet go to http://www.isispharm.com or http://www.firstcallevents.com/service/ajwz398765671gf12.html. A replay of the webcast will be available at these addresses for up to 30 days.
Isis Pharmaceuticals, Inc., is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has successfully commercialized the worlds first antisense product, and has 11 antisense products in development. In the companys GeneTrove program, Isis uses antisense technology as a tool to determine the function of genes and uses that information to direct the companys internal drug discovery research and that of its corporate partners. Through its Ibis Therapeutics program, Isis is developing a novel diagnostic tool to detect infectious organisms and is focused on the discovery of small molecule drugs that bind to RNA. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
ARROW ACQUISITION, LLC
DATED AS OF MARCH 28, 2004
TABLE OF CONTENTS
ARTICLE 1 The Merger
Copyright © 2013 The Consus Group LLC
Contact Us ·